5-Benzyl-4,6-dimethyl-pyrimidin-2-ylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Benzyl-4,6-dimethyl-pyrimidin-2-ylamine
• 英文别名: 5-benzyl-4,6-dimethylpyrimidin-2-amine
• 化学式: C₁₃H₁₅N₃
• 分子量: 213.28
• InChiKey: OOXQQUJJUAIJJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (E)-4-amino-3-benzylpent-3-en-2-one 、 氰胺 以98%的产率得到
  参考文献：
  名称：

  ALBEROLA, ANGEL;ANDRES, CELIA;GONZALEZ, ORTEGA ALFONSO;PEDROSA, RAFAEL;VI+, SYNTH. COMMUN., 17,(1987) N 11, 1309-1314

  摘要：

  DOI：

文献信息

• Formulation of immunopotentiators
  申请人：Singh Manmohan

  公开号：US20120177681A1

  公开（公告）日：2012-07-12

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以被吸附到不溶性金属盐中，例如铝盐，以修改它们的药代动力学、药效学、肌肉内滞留时间和/或免疫刺激作用。免疫增强剂被改性以引入一个基团，例如膦酸盐基团，可以介导吸附。即使以吸附形式传递，这些改性化合物也可以保留或改善它们在体内的免疫活性。
• ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
  申请人：Singh Manmohan

  公开号：US20130274465A1

  公开（公告）日：2013-10-17

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以吸附到不溶性金属盐上，例如铝盐，以改变它们的药代动力学、药效学、肌肉内滞留时间和/或免疫刺激作用。免疫增强剂被修改以引入一个基团，例如磷酸酯基团，可以介导吸附。即使以吸附形式输送，这些修改的化合物仍然可以保持或改善它们的体内免疫活性。
• PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF
  申请人：Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i.

  公开号：EP3195867A1

  公开（公告）日：2017-07-26

  The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.

  本发明提供了通式（I）的嘧啶化合物，它们能同时减少一氧化氮（NO）和前列腺素 E2（PGE2）的产生。它们对细胞的存活能力没有负面影响，在减少这些因子产生达 50%的浓度下，它们没有细胞毒性。此外，本发明还提供了通式(I)嘧啶化合物的制备方法、含有 2-甲酰基的嘧啶化合物的药物组合物，以及这些化合物用于治疗炎症和癌症疾病的方法。
• ADJUVANTED FORMULATIONS OF BOOSTER VACCINES
  申请人：NOVARTIS AG

  公开号：US20130236492A1

  公开（公告）日：2013-09-12

  The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
• ADJUVANTED FORMULATIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS
  申请人：Bagnoli Fabio

  公开号：US20140363461A1

  公开（公告）日：2014-12-11

  The efficacy of S. aureus vaccines can be enhanced by adjuvanting S. aureus antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. A S. aureus antigen can also be adsorbed to the metal salt.